Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproTSE:8086 +0.39%70 Pretax Margin % is 0.72% as of Mar. 2026, which is 82% below its 10-year median of 4.08. GuruFocus rates TSE:8086 with a GF Score™ of 70/100 and a GF Value™ of 円1,457.04 (Fairly Valued). The stock has 6 warning signs investors should review. Among 818 Medical Devices & Instruments companies, Nipro ranks better than 53.67% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Nipro's Pre-Tax Income for the
three
months ended in Mar. 2026 was 円1,242 Mil. Nipro's Revenue for the
three
months ended in Mar. 2026 was 円173,233 Mil. Therefore, Nipro's pretax margin for the quarter that ended in Mar. 2026 was 0.72%.
The historical rank and industry rank for Nipro's Pretax Margin % or its related term are showing as below:
TSE:8086'
s Pretax Margin % Range Over the Past 10 Years
Min: -2.3 Med: 4.08 Max: 5.09
Current: 4.46
TSE:8086's Pretax Margin % is ranked better than 53.67% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.505
vs TSE:8086: 4.46
Nipro (TSE:8086) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Nipro Pretax Margin % Related Terms
Nipro Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Nipro's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:8086 vs ISRG, BDX, MDLN: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nipro's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Nipro's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (TSE:8086) has a Pretax Margin % of 0.72% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nipro and its competitors. This is 82% below median its historical median of 4.08. According to the industry distribution chart, Nipro ranks #379 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 46.3%.
Is Nipro's Pretax Margin % too high?
Nipro's current Pretax Margin % of 0.72% is 82% below median its 10-year median of 4.08. The Medical Devices & Instruments industry median Pretax Margin % is 2.51. Nipro's value of 0.72% is 71.3% below this industry median. Based on the distribution chart, Nipro ranks #379 out of 818 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nipro has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nipro's Pretax Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #379 out of 818 companies for Pretax Margin %. This puts Nipro in the upper half of its industry. The industry median Pretax Margin % is 2.51. Nipro's value of 0.72% is 71.3% below this benchmark. While the company's 10-year median is 4.08 vs. the industry median of 2.51, Nipro has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.51, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nipro's current Pretax Margin % of 0.72% is 71.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nipro and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nipro's current Pretax Margin % is 0.72%, which is 82% below median its own 10-year median of 4.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Based on GuruFocus' analysis, Nipro (TSE:8086) is currently considered Fairly Valued. The stock's GF Value™ is 円1,457.04, compared to a current price of 円1,552.50 — trading 6.6% above its estimated fair value. The current Pretax Margin % is 0.72%, which is 82% below median its 10-year median of 4.08 and 71.3% below the Medical Devices & Instruments industry median of 2.51. Nipro's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Nipro (TSE:8086), the current Pretax Margin % is 0.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (TSE:8086) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of 円1,552.50 is trading 6.6% above its estimated GF Value™ of 円1,457.04.
GuruFocus considers Nipro to be Fairly Valued.
Key valuation signals for TSE:8086:
Pretax Margin %: 0.72% (82% below median its 10-year median of 4.08)
GF Value™: 円1,457.04 vs. price of 円1,552.50 (6.6% above fair value)
Industry Position: 71.3% below the Medical Devices & Instruments median (#379 of 818)
No single metric tells the full story. See the TSE:8086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
70GF Score
Get the complete analysis for TSE:8086
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:8086 has been successfully added to your 
